VivoSeq
Oncology

Ovarian Cancer Recurrent

8

Pipeline Programs↗

2

Active Trials↗

4

Companies Involved↗

Ovarian Cancer Recurrent is an early-stage landscape with 8 programs across 4 companies. The most active players are Merck & Co., Avyxa, Teva.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

4 programs

PreclinicalA

Avyxa

1 program

PreclinicalTeva logo

Teva

1 program

PreclinicalJohnson & Johnson logo

Johnson & Johnson

1 program

Preclinical

Pipeline

Programs by Phase

Preclinical8

Raludotatug Deruxtecan

Merck & Co.

Carboplatin

Avyxa

Paclitaxel

Teva

Bevacizumab

Bio-Thera Solutions

Rescue Medication

Merck & Co.

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

7programs
Small molecule457%
Monoclonal antibody229%
Antibody–drug conjugate114%

Modality classified for 78% of 9 pipeline programs.

Analysis

Trial Status

2

clinical trials

Recruiting2 · 100%

Clinical Trials

Trial Activity

SOPRANO: Stereotactic Radiotherapy Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARP Inhibitor Therapy
Recruiting·IInstitute of Cancer Research, United Kingdom·Phase 2·NCT05990192·42 enrolled
A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Relapsed After Prior Platinum-based Chemotherapy
Recruiting·Merck & Co. logoMerck & Co.·Preclinical·NCT06843447·460 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)